In this issue:
Sotorasib for lung cancers with KRAS p.G12C mutation
Acquired resistance to KRASG12C inhibition in cancer
Neoadjuvant durvalumab ±SBRT in early-stage NSCLC
Switch-maintenance gemcitabine after first-line chemotherapy in malignant mesothelioma
Rucaparib in BAP1- or BRCA1-deficient mesothelioma
Pembrolizumab in advanced mesothelioma
Immune checkpoint inhibitors for NSCLC with leptomeningeal metastases
Pembrolizumab + chemotherapy-induced pneumonitis in nonsquamous NSCLC
Drug-based prognostic score for advanced NSCLC treated with first-line immunotherapy
188Re-HEDP for lung cancer with bone metastases
Please login below to download this issue (PDF)